Overview

Phase 1 Dose Escalating Study to Assess Safety, Tolerability, Food Effect and PK of CHR-5154 in Healthy Male Volunteers

Status:
Terminated
Trial end date:
2014-05-28
Target enrollment:
Participant gender:
Summary
Primary Objective: • To determine the safety and tolerability of single and multiple ascending oral doses of CHR-5154 in healthy volunteers. Secondary Objectives: - To determine the pharmacokinetic profile of CHR-5154 and its metabolite CHR-5426. - To compare the pharmacokinetic profile of CHR-5154 and CHR-5426 after a single dose of CHR-5154 in the fed and fasted state.
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline